Publication: The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Open/View Files
Date
2015
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Faculty of 1000 Ltd
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Brown, Kristin K., and Alex Toker. 2015. “The phosphoinositide 3-kinase pathway and therapy resistance in cancer.” F1000Prime Reports 7 (1): 13. doi:10.12703/P7-13. http://dx.doi.org/10.12703/P7-13.
Research Data
Abstract
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service